NewEdge Advisors’s BioNTech BNTX Stock Holding History

NewEdge Advisors’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.61K	Hold	71	–	–	﹤0.01%	3637
2026 Q1	$6.31K	Sell	71 -4,747	-99%	-$488K	﹤0.01%	3520
2025 Q4	$459K	Sell	4,818 -1,615	-25%	-$163K	﹤0.01%	2034
2025 Q3	$634K	Sell	6,433 -92	-1%	-$9.84K	﹤0.01%	1676
2025 Q2	$695K	Buy	6,525 +4,690	+256%	+$474K	﹤0.01%	1501
2025 Q1	$167K	Buy	+1,835	New	+$205K	﹤0.01%	2157
2023 Q3	–	Sell	-40	Closed	-$4.32K	–	3486
2023 Q2	$4.32K	Sell	40 -2,845	-99%	-$320K	﹤0.01%	2866
2023 Q1	$359K	Buy	2,885 +2,625	+1,010%	+$360K	﹤0.01%	1282
2022 Q4	$38.9K	Buy	+260	New	+$40K	﹤0.01%	1830
2021 Q4	–	Sell	-1,610	Closed	-$440K	–	1641
2021 Q3	$440K	Buy	1,610 +109	+7%	+$34.6K	0.01%	779
2021 Q2	$336K	Buy	+1,501	New	+$283K	0.01%	860

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

GSK plc London $602M AUM

NewEdge Advisors's BNTX Position: Q2 2026 in Review

NewEdge Advisors held its BioNTech (BNTX) position steady in Q2 2026 at 71 shares worth $6.61K. The position accounts for ﹤0.01% of the portfolio, ranked #3637.

NewEdge Advisors first reported a position in BNTX in Q2 2021 and has held it in 11 quarters since. The position peaked at $695K in Q2 2025. 283 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

NewEdge Advisors held 71 shares of BioNTech worth $6.61K as of Q2 2026.
NewEdge Advisors left its BioNTech share count unchanged in Q2 2026.
BioNTech made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3637 holding.
NewEdge Advisors first reported a position in BioNTech in Q2 2021 and has held it in 11 quarters since.
NewEdge Advisors's BioNTech position peaked at $695K in Q2 2025.
283 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.